Bionumerik pharmaceuticals acquired

Author: gfte

August undefined, 2024

WebAcquired Party. BioNumerik Pharmaceuticals, Inc. Granting Status. Granted. Acquired Entities. BioNumerik Pharmaceuticals, Inc. More Resources. HSR Annual Reports; … WebCompany Description: BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential …

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly ...

WebJan 21, 2010 · SAN ANTONIO, Jan. 21 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, … WebNov 8, 2012 · BioNumerik Pharmaceuticals raised $10,190,500 / Series Unknown. Discover more funding rounds . Funding Round ... sharco international

20050090: Takeda Pharmaceutical Company Limited; …

WebAug 9, 2024 · LP-300 was in-licensed from BioNumerik Pharma in May 2016 and acquired from them in January 2024. Following acquisition of the license, Lantern planned a … WebJun 14, 2012 · SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve Carchedi to BioNumerik's Board of Directors.. Mr. Carchedi brings extensive pharmaceutical industry and oncology product commercialization experience to the … WebBionumerik Pharmaceuticals designs and develops small molecule drugs for the treatment of cancer and prevention of side effects associated with existing cancer therapies. sharc melbourne

BioNumerik Pharmaceuticals - Products, Competitors, Financials ...

Bionumerik pharmaceuticals acquired

BioNumerik Pharmaceuticals, Inc. and ASKA Pharmaceutical

Web51 to 200 Employees. Type: Company - Private. Industry: Biotech & Pharmaceuticals. Revenue: $5 to $25 million (USD) Competitors: Unknown. BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late ... WebAug 8, 2016 · On Aug 8, 2016. Lantern Pharma has entered into an exclusive agreement to evaluate BioNumerik Pharmaceuticals’ Tavocept for human therapeutic indications using Lantern’s 5-M theranostic platform. Tavocept is an investigational new drug candidate from BioNumerik’s portfolio that has shown potential for both oncology and non-oncology ...

Did you know?

WebAug 27, 2009 · BioNumerik Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT00966914 Other Study ID Numbers: DMS32212R : First Posted: August 27, 2009 Key Record Dates: Last Update Posted: July 13, 2024 Last Verified: July 2024 Additional relevant MeSH terms: Layout table for MeSH terms ... WebAug 9, 2016 · Aug. 09, 2016 02:42PM PST. Pharmaceutical Investing. DALLAS– (EON: Enhanced Online News)–Lantern Pharma, Inc. (Dallas, TX, US) and BioNumerik Pharmaceuticals, Inc. of San Antonio, Texas have ...

WebBioNumerik Pharmaceuticals, Inc. Lantern Pharma, Inc. By: /s/ David R. Margrave : By: /s/ Arunkumar Asaithambi: Name: Name: Arunkumar Asaithambi, Ph.D. Title: Title: Chief … WebOct 6, 2004 · LINCOLNSHIRE, Ill. (October 7, 2004) – Takeda Pharmaceutical Company Limited (“Takeda”), the Osaka, Japan-based parent company of Takeda …

WebJun 14, 2012 · SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve … WebFunding. BioNumerik Pharmaceuticals has raised a total of $63.3M in funding over 3 rounds. Their latest funding was raised on Nov 8, 2012 from a Venture - Series Unknown round. BioNumerik Pharmaceuticals is funded by Takeda. BioNumerik Pharmaceuticals has a post-money valuation in the range of $10M to $50M as of Dec 31, 2012, according …

WebJan 21, 2010 · BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas, is focused on the discovery, development and commercialization of novel drugs for the …

WebAcquired Party. BioNumerik Pharmaceuticals, Inc. Granting Status. Granted. Acquired Entities. BioNumerik Pharmaceuticals, Inc. More Resources. HSR Annual Reports; … poolcovertechWebNov 18, 2024 · 31% of BioNumerik Pharmaceuticals employees are Asian. 18% of BioNumerik Pharmaceuticals employees are Hispanic or Latino. The average … pool cover stretcherWebAug 1, 2006 · BioNumerik has two drug candidates in late-stage clinical development: Tavocept(TM) and Karenitecin (BNP1350). Contacts: Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) Seizo Masuda [email protected] Tel: +81-6-6204-2060 BioNumerik Pharmaceuticals, Inc. … pool covers that heat the water